Every day seems to bring new breakthroughs in the diagnosis and treatment of Alzheimer’s.
Medical News Today recently reported that research conducted at the Amsterdam University Medical Center resulted in the development of a promising model that may enable healthcare professionals to predict the various stages of cognitive decline in individuals with Alzheimer’s disease.
The FDA recently announced the approval of a new medication to target the proteins that interfere with the transmission of nerve impulses. The announcement came hot on the heels of recent news about a synthetic peptide that may reduce the production of these proteins.
Medical News Today now reports on an AI-based tool capable of predicting whether a person with early dementia symptoms will either remain stable or progress to Alzheimer’s disease. Here’s the start of the story:
While the terms dementia and Alzheimer’s disease are often used interchangeably, they are not the same.
Dementia is an umbrella term for conditions that negatively affect thinking, memory, and a person’s ability to do their daily tasks. Alzheimer’s disease is a specific neurological condition and is the most common type of dementia, accounting for 60-80% of all dementia diagnoses.
With both dementia and Alzheimer’s disease, early diagnosis is key to help slow disease progression. However, previous studies show that less than half of people with dementia symptoms are ever diagnosed.
And because dementia and Alzheimer’s disease both share common symptoms of natural age-related cognitive decline, making early diagnosis of either condition is many times difficult.
In an effort to help solve this issue, researchers from the University of Cambridge have developed a tool using artificial intelligence (AI) that is capable of predicting whether or not a person with early dementia symptoms will either remain stable or progress to Alzheimer’s disease.
The study was recently published in the journal eClinical Medicine.